Reaction
Monocyte Count Decreased reporting signals
As of the last recalculation, Monocyte Count Decreased appears in 1,196 FAERS reports alongside 37 co-occurring drug terms. The strongest observed disproportionality signal is ALEMTUZUMAB (PRR 77.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Alemtuzumab | 80 | 77.1 | 77.4 |
| Dimenhydrinate | 41 | 69.3 | 69.6 |
| Ribociclib | 57 | 33.0 | 33.0 |
| Cimetidine | 17 | 31.1 | 31.2 |
| Letrozole Tablets | 57 | 21.6 | 21.6 |
| Letrozole | 71 | 21.3 | 21.3 |
| Clozapine | 132 | 20.4 | 20.5 |
| Cladribine | 10 | 18.3 | 18.3 |
| Paliperidone | 22 | 16.7 | 16.7 |
| Fesoterodine Fumarate | 10 | 16.2 | 16.2 |
| Fulvestrant | 30 | 16.2 | 16.2 |
| Sennosides 8.6 Mg Tablets | 18 | 15.2 | 15.2 |
| Senna | 18 | 15.1 | 15.1 |
| Senna Leaf | 19 | 14.5 | 14.6 |
| Blinatumomab | 8 | 13.4 | 13.4 |
| Felodipine Extended-Release Tablets | 8 | 12.3 | 12.3 |
| Felodipine | 8 | 12.3 | 12.3 |
| Palbociclib | 62 | 11.9 | 11.9 |
| Temozolomide | 14 | 11.7 | 11.7 |
| Valproic Acid | 20 | 11.2 | 11.2 |
| Imatinib | 10 | 9.9 | 9.9 |
| Pemetrexed | 12 | 9.8 | 9.8 |
| Desoximetasone | 10 | 9.2 | 9.2 |
| Niraparib | 11 | 8.7 | 8.7 |
| Lurasidone Hydrochloride | 9 | 7.5 | 7.5 |
| Fingolimod Hcl | 36 | 7.4 | 7.4 |
| Paclitaxel (Aibumin-Bound) | 32 | 6.9 | 6.9 |
| Docetaxel Anhydrous | 26 | 6.8 | 6.8 |
| Docetaxel | 26 | 6.8 | 6.8 |
| Eculizumab | 21 | 6.8 | 6.8 |
| Brentuximab Vedotin | 4 | 6.8 | 6.8 |
| Ravulizumab | 5 | 6.5 | 6.5 |
| Pemetrexed Disodium | 14 | 6.5 | 6.5 |
| Iohexol | 3 | 6.3 | 6.3 |
| Azacitidine | 10 | 5.9 | 5.9 |
| Polatuzumab Vedotin | 3 | 5.4 | 5.4 |
| Trifluridine And Tipiracil | 3 | 4.9 | 4.9 |